483 sent to Jilin Shulan Synthetic Pharmaceutical Co.
Abstract:Warning letter sent to Jilin Shulan Synthetic Pharmaceutical Co. regarding significant deviations from Current Good Manufacturing Practice (CGMP) for the manufacture of APIs.
Trending Compliance Trainings
Sterile Filtration of Pharmaceutical Products - Validation and Regulatory Requirements
By - Roger Cowan
On Demand Access Anytime
By - Roger Cowan
On Demand Access Anytime
HVAC and GMP Environmental Control - for Pharmaceutical Cleanrooms
By - Roger Cowan
On Demand Access Anytime
By - Roger Cowan
On Demand Access Anytime
Extractables and Leachables in Early Phase Development
By - Wayland Rushing
On Demand Access Anytime
By - Wayland Rushing
On Demand Access Anytime
Processes & Effects of Immunogenicity to Biologics & the Screening Methodologies - 3 hour Virtual Training
By - Gwen Wise Blackman
On Demand Access Anytime
By - Gwen Wise Blackman
On Demand Access Anytime
Residual Solvents: Take Advantage of the New Flexibility in Revised USP <467>
By - Gregory Martin
On Demand Access Anytime
By - Gregory Martin
On Demand Access Anytime
The Veterinary Drug Approval Process and FDA Regulatory Oversight
By - Rob Hunter
On Demand Access Anytime
By - Rob Hunter
On Demand Access Anytime
Auditing for Microbiological Aspects in Pharmaceutical and Biopharmaceutical Manufacturing
By - Carl Patterson
On Demand Access Anytime
By - Carl Patterson
On Demand Access Anytime
Veterinary Feed Directive (VFD) Final Rule - What you need to know
By - Bernadette Alisantosa
On Demand Access Anytime
By - Bernadette Alisantosa
On Demand Access Anytime
You Recently Viewed
